Abstract. Accumulating evidence suggests that colorectal cancer (CRC) should be viewed as a heterogeneous disease, with proximal and distal CRCs showing multiple biological and clinical differences. The aim of this study was to develop a clinicopathological, molecular and protein profile for CRCs based on their region and thus providing insight into their heterogeneity. CRC patients (n=399) were evaluated for clinicopathologic and molecular features including K-RAS, BRAF and MSI status. Tumors were also screened for expression of 50 immunohistochemical markers linked to major signaling pathways involved in tumor-progression or immune response. Proximally located tumors show significantly larger tumor size, higher T-stage, higher tumor grade and more frequent mucinous histologic subtype compared to the distal colon and rectum. The frequency of BRAF mutation and MSI-high phenotype were significantly higher in proximal colon cancers. There is a significant difference in regional expression of 10 tumor-associated markers (CDX2, CD44v6, CD44s, TOPK, nuclear ß-catenin, pERK, APAF-1, E-cadherin, p21 and bcl2) and 4 immune response markers (CD68, CD163, FoxP3 and TIA-1). In multivariate analysis CD44s, CD44v6, nuclear ß-catenin and CD68 expression was found to best discriminate left-versus right-sided colon cancers. Tumor diameter, pT stage and MSI status best distinguish right-sided colon cancers from rectal cancers and pT stage and E-cadherin best discriminate left-sided colon cancers and rectal cancers. These data along with existing evidence for the presence of distinct regional embryological origin and gene expression profile are highly supportive of the concept that proximal and distal CRCs are distinct clinicopathologic entities.
Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer mortality in North America and worldwide (1) . Recent epidemiologic studies have reported a proximal migration of CRCs evidenced by increased incidence of right-sided colon cancers and a decrease in incidence of rectosigmoid tumors (2, 3) , suggestive of different risk factors associated with carcinogenesis in proximal and distal colon (4, 5) . These data support the concept originally proposed by Bufill in 1990 that cancers originating from these two different anatomical locations should have distinct molecular pathogenesis (6) . Several biological differences between the normal proximal and distal colon (relative to the splenic flexure) may contribute to tumorigenesis in these locations along different pathways. For example, they have different embryonic origins: proximal colon derives from midgut while distal colon and rectum originates from embryonic hindgut. In addition, adult mucosal epithelium of proximal and distal colon can be distinguished by their pattern of gene expression since >1,000 genes are expressed differentially in adult ascending versus descending colon (7) . Physiologically, sodium and water absorption commonly take place in proximal colon and progressively decreased toward rectum where fecal storage comprises the main physiologic function. Bacterial fermentation produces short chain fatty acids predominantly in proximal colon where they can be passively absorbed (4, 5, 8) . Furthermore, biliary salts shown to be associated with increased risk of colon cancer have higher concentration in proximal colon (8) .
Traditionally, two types of genetic instability have been described in CRC: chromosomal instability (CIN) and microsatellite instability (MSI) (9) . These tumorigenic pathways have been modeled in two familial cancer syndromes, namely familial adenomatous polyposis (FAP) and hereditary nonpolyposis coli (HNPCC) respectively. Chromosomal instability pathway in colon cancer has been characterized by sequential accumulation of genetic alterations involving activation of oncogenes (like K-RAS) and inactivation of tumor suppressor genes (like p53) in an adenoma-carcinoma sequence (10) . Microsatellite instability in CRC results from defective DNA mismatch repair function associated with either a somatic gene mutation (in familial syndrome) and/or gene methylation (in sporadic forms) (9) . Epigenomic instability characterized by CpG island methylator phenotype (CIMP) has been recently described as an alternative pathway for tumorigenesis associated with MSI in sporadic CRCs due to methylation of MLH1 mismatch repair gene (11) . CIN-and MSI-associated CRCs show a reversed pattern of distribution along the large intestine. Several studies have shown that both familial and sporadic forms of CIN-associated CRCs tend to occur in distal part of colon while MSI-associated tumors have proximal preference in both familial and sporadic forms (4, 9, 12) . It should be noted, however, that tumor phenotype is only determined by underlying molecular pathway not by anatomical site and that there is significant overlap among proximal and distal CRCs with respect to their underlying molecular mechanism. Reflecting the heterogeneous character of CRCs, recent reports indicate that a subset of CRCs is not associated with either CIN or MSI (13) . There is increasing evidence that at least part of CRCs in this group are CIMP positive phenotype associated with lower level of gene methylation and K-RAS mutation (14) . Heterogeneity of colon cancer disease has become further evident by an emerging concept that recognizes rectal cancer as a separate entity from the rest of distal colon cancers and tends to divide CRCs into proximal colon cancer, distal colon cancer and rectal cancer (4) . Lower frequency of K-RAS mutations, higher level of p53 expression, higher cyclooxygenase-2 (Cox2) and higher nuclear ß-catenin expression are in support of this distinction (4) .
The aim of this study was to perform a comprehensive and simultaneous analysis of clinicopathological, molecular and protein expression profile on a large series of proximal and distal colon carcinomas and rectal cancers in order to provide evidence for the concept of viewing these tumors as distinct clinicopathologic entities based on their anatomic locations.
Patients and methods
Patients. Primary pre-operatively untreated, unselected sporadic CRC patients (n=1,420) treated at the University Hospital of Basel between the years 1987 and 1996 were included in this study. Hematoxylin and eosin (H&E) stained slides were retrospectively collected from the Institute of Pathology, University Hospital of Basel, the Institute of Clinical Pathology, Basel, Switzerland and the Institute of Pathology, Stadtspital Triemli, Zürich, Switzerland. Histopathological criteria were reviewed and included tumor diameter, pT and pN classification (according to the 6th edition of the AJCC Cancer Staging manual), grade of differentiation, histologic subtype, the presence of vessel invasion, the tumor border configuration (pushing/expanding or infiltrating), as well as the presence of peritumoral lymphocytic inflammation at the invasive tumor front. Clinical data including patient age at diagnosis, gender, and tumor location was reviewed concurrently. Censored observations included patients who were alive at the last follow-up, died for reasons other than CRC or who were lost to follow-up.
Specimen characteristics. A previously described single-punch tissue microarray was constructed including all 1,420 cases and 57 normal colorectal mucosa samples as controls. Briefly, one tissue cylinder 0.6 mm in diameter was punched from representative tissue areas and brought into one recipient paraffin block (3x2.5 cm) using a homemade semi-automated tissue array maker. Of these 1,420 cases, paraffin-embedded surgical resection specimens from 600 cases were available and thus retrospectively collected from the archives of the Institute of Pathology, University Hospital Basel, Switzerland for subsequent molecular analysis.
Assay methods Molecular analysis of BRAF, K-RAS and mismatch repair genes. Analysis for BRAF, K-RAS and MSI status are routinely performed at the Institute of Pathology, University Hospital Basel, Switzerland. A detailed protocol has previously been described (15) . Microsatellite stable (MSS) and MSI-low (MSI-L) status were defined as instability at 0 and 1 markers, respectively. MSI-H was characterized by the presence of instability in ≥2 markers.
Immunohistochemistry. Immunohistochemistry for the 600 CRCs included on the larger tissue microarrays was performed for 36 tumor-associated protein markers selected to represent the most important signaling pathways in colorectal tumorigenesis (WNT, RAS/MAP kinase, TGF-ß, pAKT signaling) and in processes of tumor progression (angiogenesis, metastasis, apoptosis, proliferation cell cycle, cell adhesion). Study design. The study design is outlined in Fig. 1 . Briefly, a tissue microarray of 1420 CRCs was constructed. Immunohistochemistry for all 50 markers was performed and staining evaluated. Paraffin-embedded tumor blocks (n=600) for these corresponding patients were available for subsequent DNA extraction. Molecular analysis for K-RAS, BRAF, and MSI status as well as information on tumor location was available for 399 patients.
Statistical analysis methods. Differences in tumor location and lymphocyte/inflammatory-associated protein expression were analyzed using the ¯2 or Fisher's exact test, where Table I . Tumor, lymphocyte and inflammatory cell protein markers.
- Marker of proliferation Table I . Continued. 
appropriate, whereas age and tumor diameter were analyzed using Student's t-test, and tumor-associated protein expression using the Wilcoxon rank-sum test. In order to determine the discriminatory effect of each variable on tumor location, univariate and multiple logistic regression analysis was performed. Odds ratios and 95% confidence intervals (CI) were obtained. Receiver operating characteristic (ROC) curve analysis was used to determine the appropriate cut-off scores for all tumor-associated markers and for estimating the discriminatory ability of the final multivariable model for tumor location. Analyses were performed using SAS (V9.1, Cary, NC, USA).
Results
The total number of patients entered into this study was 399.
Mutational investigations for K-RAS and BRAF were possible in 387 and 369 cases, respectively whereas analysis of MSI status was carried out for all 399 patients. We first screened clinicopathological, molecular and protein expression profile in different anatomical locations of colon and rectum to rule in features/markers that show significant regional difference. We then used these parameters to compare three different regions of colon and rectum in a pair-wise fashion. (Table II) . Our initial screening showed multiple clinicopathological/molecular features with significant regional differences. These features include tumor size (p<0.001), T-stage (p<0.001), grade (p<0.001), mucinous histologic type (p=0.038), BRAF gene mutation (V600E) (p=0.002) and microsatellite instability (MSI-H) (p=0.002). No significant survival time differences were noted between left-sided, right-sided and rectal cancers, although a trend toward worse outcome with right-sided tumor location was observed. Also there was no significant regional difference among CRCs with respect to gender, patient age at the diagnosis, N-stage, vascular invasion, tumor margin type (infiltrating/pushing), peritumoral lymphocytic infiltration and K-RAS mutation (codon 12 or 13). Tables III and IV) . We then screened protein expression profiles in specific anatomical regions of colon and rectum which led to the selection of markers showing significant variation in expression among different regions, including CDX2 (p<0.001), CD44v6 (p=0.012), CD44s (p<0.001), TOPK (p=0.008), nuclear ß-catenin (p=0.003), pERK (p=0.042), APAF-1 (p=0.041), E- Figure 1 . Study design. Briefly, a tissue microarray of 1420 CRCs was constructed. Immunohistochemistry for all 50 markers was performed and staining evaluated. Six hundred paraffin-embedded tumor blocks for these corresponding patients were available for subsequent DNA extraction. Molecular analysis for K-RAS, BRAF, and MSI status as well as information on tumor location was available for 399 patients. Table II . Differences in clinicopathological and molecular features stratified by tumor location (left-sided, right-sided and rectum).
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Differences in tumor-and immune response-associated protein expression by tumor location (
Left-sided Rectum Right-sided P- value  --------------------------------------------------------------------------------------------------- 1)  ----------------------------------------------------------------------------------------------------- cadherin (p=0.004), p21 (p=0.003) and uPA (p=0.005). Several immune response associated markers showed significant difference among proximal colon, distal colon and rectum. These include CD68 (p=0.003), CD163 (p=0.013), Foxp3 (0.002) and TIA-1 (0.035).
Association of significant predictive parameters with specific tumor locations (Table V).
In the next step, we compared predictive parameters among three distinct tumor locations in a pair-wise fashion. When clinicopathological features were compared in different regions, right-sided tumors showed a significantly larger tumor diameter, a more advanced pT stage and a higher tumor grade compared to left-sided tumors (p=0.002, 0.012 and 0.009 respectively) and rectal cancers (p<0.001, p<0.001, p=0.003 respectively). The only clinicopathological difference between left-sided colon cancers and rectal cancers was advanced T-stage in the former (p=0.01). Mucinous histologic feature showed a significant difference only when right-sided tumors were compared with rectal cancers (p=0.014). With regards to molecular features, MSI-H was significantly more common in proximal colon cancers when compared to distal colon (p=0.026) and rectal (p=0.001) cancers. BRAF mutation status was significantly different only if rectal and proximal colon cancers were compared (p=0.001).
In the tumor marker/immune response marker category, negative expression of CDX2, ß-catenin and pERK and positive expression of CD44s, CD44v6, CD68, and CD163 differentiated proximal from distal colon cancers (p=0.002, p<0.001, p=0.021, p<0.001, p=0.001, p<0.001, p=0.005, respectively).
Positive expression of TOPK, APAF-1, p21, uPA, Foxp3 and TIA-1 and negative expression of CDX2 and ß-catenin were capable of differentiating right-sided colon from rectal cancers (p=0.013, 0.008, 0.026, 0.007, 0.002, 0.006, p<0.001, p=0.005, respectively).
Finally, positive expression of CD44v6, E-cadherin, CD68, CD163 and Foxp3 were found significantly more frequently in rectal cancers compared to left-sided colon cancers (p=0.014, 0.009, 0.047, 0.007 and 0.006). (Table VI) . In order to identify the most discriminating and independent predictive factors for specific tumor locations, significant features/markers in Table V were reanalyzed using multivariate analysis (Table VI) . Independent predictors of proximal colon cancers compared to distal tumors included CD44s positivity (p=0.037), CD44v6 positivity (p<0.001) and negativity for ß-catenin (p<0.001) as well as higher numbers of CD68 positive cells (p=0.017). No protein marker was able to best differentiate proximal colon cancers from rectal tumors. However, clinicopathological/ molecular features including higher tumor diameter (p=0.005), higher T-stage (p=0.002) and more frequent MSI-H status (p=0.033) were capable of making this distinction. Rectal cancers can be best distinguished from left colon cancers by lower T-stage (p=0.004) and higher E-cadherin expression (p=0.016) (Table VI) .
Most discriminatory factors characterizing distinct tumor locations
Discussion
The results of our study on 399 CRCs show the presence of several differences between cancers originating from proximal colon, distal colon and rectum with respect to their clinicopathological, molecular and protein profiles.
Clinical data analysis revealed that right-sided tumors are significantly larger than tumors in the rest of colon and rectum. Furthermore, T-stage could discriminate right-sided Table III . Mean protein expression (%) and differences by tumor location (left-sided, rectum, right-sided).
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Left-sided Rectum Right-sided P-value markers Table IV . Lymphocyte/inflammatory marker expression and differences by tumor location (left-sided, rectum, right-sided).
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Left-sided Rectum Right-sided cancers from left-sided colon and rectal cancers (Table V) with rectal cancers showing the lowest T-stage. Interestingly, in the multivariate analysis, T-stage showed independent predictive value for discriminating rectal cancers from proximal and distal colon cancers (Table VI) . Some studies have suggested a direct association between increasing age, female sex and proximal location in colon cancers (16) . However, our data, in line with some other studies (17,18), do not support this association (Table II) . We found that proximal cancers exhibit significantly higher tumor grade as compared to distal colon (p=0.009) and rectal cancers (p=0.003) ( Table V) . This is in agreement with two previous reports (12, 16) , whereas other studies did not show any regional difference in tumor grade (17) . Furthermore, mucinous tumors were found more frequently in the right side only when it was compared to rectum (p=0.014) ( Table V) . This finding is also in agreement with some (5, 12, 16, 17) but not all previous reports (19, 20) . Survival was not affected by tumor location in our hands (Table II) contrary to studies reporting a better survival for proximal colon cancers (8, 12 ) and a worse survival for rectal tumors (21).
P-value -----------------------------------------------------------------------------------------------------
Our results were also significant for a regional difference in CRC genetic profile. In accordance to most previous reports, our data indicate that MSI-H status is more common in proximal colon cancers as compared to distal colon (p=0.026) and rectum (p=0.001) (Table V) (5, 6, 12, 17) . However, BRAF mutation showed a significant difference only when rightsided and rectal cancers were compared (Table V) . Using molecular data, MSI-H status was able to independently predict proximal colon location in the multivariate analysis only when proximal colon cancers were compared to rectal cancers (Table VI) . No significant regional difference was identified for K-RAS mutation which is contrary to prior reports showing more frequent K-RAS mutation in proximal colon and less frequency in rectum (22, 23) . K-RAS mutation has recently been recognized as the best predictor of CIMP-low or CIMP2 CRCs that are characterized by lacking both MSI and CIN (Introduction) and not showing any regional preference (13, 14) . Our data from regional K-RAS mutation analysis are in support of this concept.
We also examined regional differences in expression of tumor marker proteins as well as immune response markers Table IV . Continued. (Tables III-V) . CDX2, CD44s, TOPK, nuclear ß-catenin, pERK, APAF-1, E-cadherin, p21 and uPA were the only tumor markers and CD68, CD163, Foxp3 and TIA-1 were the only immune response markers that showed significant regional 
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a OR, odds ratio. CI, confidence interval. NS, not significant. Table VI . Most discriminatory factors characterizing specific tumor locations in multivariable analysis.
left OR (95%CI) P-value Right vs. rectum OR (95% CI) P-value Rectum vs. left OR (95% CI) P-value (Tables III and IV) . These markers were used to compare three CRC locations in pairs to specify regions with significantly higher or lower expressions. Based on this analysis, proximal colon cancers can be differentiated from distal colon cancers by negative CDX2, and nuclear ß-catenin expression, higher CD44s expression and more frequent CD68 and CD163 positive cells (Table V) . Loss of CDX2 expression in right-sided tumors was independent of MSIstatus confirming previous reports (24, 25) . When these results were adjusted for multiple testing, only CDX2 expression loss and CD44 overexpression were selected as discriminator between right-and left-sided colon cancers (p<0.001, both). In clinical practice a panel of CDX2 + CK7 -and CK20 + has been traditionally employed to confirm a colorectal cancer origin in the case of metastasis of unknown primary (26) . This is, however, inconsistent with the finding of CDX2 expression loss in subset of colon cancers especially those occur in right side. Therefore, loss of CDX2 expression should be interpreted with caution for diagnostic purposes.
Our data show that CD44s and CD44v6 expression has an independent predictive value in differentiating proximal colon from distal colon cancers in a multivariate analysis (Table VI) . In addition, further analysis showed a direct association between CD44s expression and MSI-high status (p=0.031). CD44 has recently emerged as a stem cell marker (27, 28) . These results may suggest a distinct, CD44s-positive stem cell for MSI-high colon cancers, however, CD133 and CD166, the other stem cell markers, did not show any significant regional difference in expression (Table III) . Peritumoral macrophage infiltration could correctly classify proximal from distal tumors evidenced by a higher CD68 expression. Marked infiltration of tumor by lymphocyte is shown to be associated with MSI-high status (29) , however, we did not detect any significant regional difference in CD8-positive tumor infiltrating lymphocytes (TILs) ( Table IV) . Negative nuclear ß-catenin was another independent predictive marker capable of differentiating proximal colon from distal colon cancers in a multivariate analysis (Table VI) which is consistent with previous data associating left-sided colon cancers with chromosomal instability and APC/catenin pathway (Introduction).
Proximal colon tumors can be distinguished from rectal tumors by negative CDX2 and ß-catenin expression, higher TOPK, APAF-1, p21 and uPA expression and less frequent Foxp3 positive cells (Table V) . We found that p21 is significantly more expressed in right-sided colon cancers compared to rectal cancers in contrast to previous reports (30) showing no regional difference. Also we did not detect any significant difference in regional expressions of p27 and P53 contrary to previous studies that show higher P53 expression in distal colon and rectum (5, 12, 31) and a lower expression of p27 in proximal colon tumors (17, 32) . Cox2 is reported to be more expressed in distal colon or rectal cancers (4,33) however, we did not detect any significant regional Cox2 expression (Table III) . Multivariate analysis showed that higher tumor diameter, higher T-stage and MSI-H status are the best discriminatory factors to differentiate proximal colon cancers from rectal tumors (Table VI and Fig. 2) .
Tumors located in the rectum demonstrated more similarity to tumors located in distal colon in terms of clinicopathological, molecular and protein expression profile. Higher E-cadherin expression and more frequent CD68, CD163 and Foxp3 positive cells were the only markers that were able to differentiate rectal cancers from the tumors in distal colon (Table V) . In multivariate analysis, lower T-stage and higher E-cadherin expression were the best independent predictors in differentiating rectal cancers from left-sided colon cancers (Fig. 2) .
Taken together, our data indicate the presence of significant regional differences in CRCs with respect to their clinicopathological, molecular pathogenesis and protein profile. The distinction is more prominent when proximal colon cancers are compared with distal colon and rectal cancers and less dramatic in comparison between distal colon and rectal cancers. These data along with existing evidence for the presence of distinct regional embryological origin and gene expression profile are highly supportive of the concept that proximal and distal CRCs are distinct clinicopathologic entities. This concept has practical implications in prevention and treatment of both familial and sporadic CRCs.
